Open AccessEvaluation of efficacy and safety of intravenous immunoglobulin IG VENA in patients with primary antibody synthesis immunodeficiency
Author(s) -
Elena A. Latysheva,
Т В Латышева,
I A Martynova
Publication year - 2016
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja364
Subject(s) - medicine , antibody , primary immunodeficiency , immunotherapy , immunodeficiency , drug , immunology , intravenous drug , human immunodeficiency virus (hiv) , intensive care medicine , pharmacology , immune system , viral disease
Replacement immunotherapy with intravenous immunoglobulin (IVIG) has been used successfully for the treatment of primary immunodeficiency (PID) for over 60 years. During this time, a huge step forward in purification and manufacturing methods has been made. In addition IVIG therapy has been approved for other diseases and this number is steadily expanding causing an appearance of new IVIG on the pharmaceutical market. These drugs vary in composition, manufacturing technology and, as a consequence, in safety, administration rate, and efficacy. The new IVIG on the Russian market IG Vena was recently introduced. It has already proved its safety and efficacy abroad. This article presents the experience of using the drug IG Vena in adults with PID in immunopathology department of the Institute of Immunology FMBA Russia.